MELLIsim is a start-up created to put the MELLIsense CGM solution on the market to address the huge unmet needs of Type 2 Diabetic (T2D) patients. MELLIsim’s goal is to put on the market the promising continuous glucose sensor technologies. The MELLIsense medical device replaces multiple painful daily finger-prick glucose measurements by a wearable biosensor patch associated with a proprietary software application available on the patient smartphone.
MELLIsim is a start-up created to put the MELLIsense CGM (Continuous Glucose Monitoring) solution on the market to address the huge unmet needs of Type 2 Diabetic (T2D) patients. We developed our innovative glucose sensor technology in collaboration with ITODYS, one of the leading research laboratories in electrochemical biosensors in France. Our innovation radically changes the care of T2D patients: 70% of them with one insulin injection per day currently fail to reach a normal glycaemic control. The MELLIsense medical device replaces multiple painful daily finger-prick glucose measurements by a wearable biosensor patch associated with a proprietary Artificial Intelligence application available on the patient smartphone. MELLIsense’s unique combination provides patients with clinical expertise of diabetes specialists through personalised analyses and recommendations. It allows patients to leverage the best clinical practices, including a personal diabetes coach available anywhere and at any time to motivate and engage patients in their daily treatment. MELLIsim is working with the support of patient associations and renowned hospital specialists in France, Switzerland, UK and Canada. We plan to sell our solution at the same price as the current practice with BGM (Blood Glucose Measurement) using finger-pricks to measure glycaemia, which are 2 to 8 times cheaper than competitor CGM solutions. We validated the efficiency of the concept on Human in 2018. In 2019 we tested our biosensor during preclinical trials. In 2020, we focused on the sensor miniaturisation and on the automation of the manufacturing process. This year we will do the first in human acute tests of our sensor and continue the clinical trials in 2022. We plan to obtain CE mark and FDA approval for our CGM sensor in Q2 2023 and to deliver to patients the full MELLIsense solution by the end of 2023. We are looking for investors, industrial and distribution partners.
$ 2.5 Millions - $ 5 Millions
Leave a Reply